Quarterly ResultAug 12, 2026, 06:32 AM
Annexon Expands Vonaprument GA Phase 3 with Dual Primary Endpoint
AI Summary
Annexon reported its second quarter 2026 financial results and provided significant business updates. The company expanded its vonaprument Phase 3 ARCHER II program for Geographic Atrophy (GA) to include a Month 24 dual primary endpoint, complementing the existing Month 15 endpoint, and launched an open-label extension study. Annexon also announced progress in its GBS program with a BLA submission expected in Q4 2026, anticipated POC data for ANX1502 in Fall 2026, and secured a $200 million credit facility extending its cash runway into 2028. For Q2 2026, the net loss was $55.3 million.
Key Highlights
- Vonaprument Phase 3 ARCHER II program expanded with Month 24 dual primary endpoint for GA.
- Launched open-label extension study for long-term safety and benefit of vonaprument.
- Tanruprubart GBS program expects BLA submission in Q4 2026.
- ANX1502 POC data for autoimmune disease anticipated in Fall 2026.
- Secured $200 million credit facility, extending cash runway into 2028.
- Q2 2026 net loss was $55.3 million, or $0.28 per share.
- R&D expenses for Q2 2026 were $46.6 million.
- Cash, cash equivalents, and short-term investments totaled $209.2 million as of June 30, 2026.
Price Impact
More from ANNX